This medication has a taste of olive oil. Deltius can be taken alone or by mixing the solution with a small amount of cold or lukewarm food immediately before ingestion. Make sure to take the complete dose.
Use in adults
The recommended dose is 1 vial of 25,000 UI per week for the first month. After the first month, the dose may be reduced.
Higher doses may be required:
-50,000 UI/week for 6 – 8 weeks;
This initial treatment may be followed by a maintenance therapy, as indicated by your doctor.
Your doctor will adjust the dose for you.
Pediatric population
Deltius is not recommended for children and adolescents under 18 years of age.
Use during pregnancy and lactation
Deltius is not recommended.
If you take more Deltius than you should
If you take more than the prescribed amount, stop taking the medication and call your doctor. If you cannot contact your doctor, go to the nearest hospital emergency service and bring the packaging with the medication.
You can also contact the Toxicological Information Service, phone 915620420, indicating the medication and the amount taken.
The most common symptoms of overdose are: nausea, vomiting, excessive thirst, excessive urine production for up to 24 hours, constipation, dehydration, and elevated levels of calcium in the blood and urine (hypercalcemia and hypercalciuria) determined by clinical tests.
If you forget to take Deltius
If you forget to take a dose of Deltius, take the next dose as soon as possible. Then, take the next dose at the usual time. However, if you are close to the time of the next dose, do not take the missed dose and instead take the next dose at the usual time.
Do not take a double dose to make up for the missed doses.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like any other medication, Deltius may produce adverse effects, although not all people will experience them.
The possible adverse effects associated with the use of Deltius may be:
Rarely Occurring(affect 1 in 100 people):
- Hypercalcemia (excess calcium in the blood)
- Hypercalciuria (excess calcium in the urine)
Uncommon(affect 1 in 1000 people):
- Cutaneous rash (hives or skin eruption)
- Pruritus (itching)
- Urticaria
Reporting Adverse Effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store above 25 °C.
Do not refrigerate or freeze.
Store in the original packaging to protect it from light.
Do not use this medication if the solution appears cloudy.
Medications should not be disposed of through drains or trash. Deposit empty containers and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of empty containers and unused medications. By doing so, you will help protect the environment.
What Deltius contains
1 single-dose vial contains 1.25 mg of colecalciferol (vitamin D3) equivalent to 50,000 UI.
Appearance of Deltius and contents of the packaging
Deltius 50,000 UI is a transparent, colorless to yellow-green oily oral solution. It is supplied in an amber glass bottle sealed with a plastic cap resistant to handling.
Each package contains 1, 2, or 4 single-dose vials containing 2.5 ml of solution.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder:
ITALFARMACO, S.A.
San Rafael, 3 – 28108 Alcobendas (Madrid),
Spain
Phone: 916572323
Manufacturer responsible:
Abiogen Pharma S.p.A.
Via Meucci, 36 –
56121 Pisa
Italy
This medicine is authorized in the Member States of the European Economic Area with the following names:
England;DELTIUS 50 000 I.U. /2,5 ml oral solution
Greece:DELTIUS 50 000 I.U. /2,5 mlπ?σιμο δι?λυμα
France:DELTIUS 50 000 I.U. /2,5 ml solution buvable
Portugal:DELTIUS 50 000 I.U. /2,5 ml solução oral
Cyprus:DELTIUS 50 000I.U. /2,5 mlπ?σιμοδι?λυμα
Last review date of this leaflet: March 2019
The detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.